TY - JOUR
T1 - The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls
T2 - Results from the EUGEI study
AU - Fusar-Poli, Laura
AU - Pries, Lotta-Katrin
AU - van Os, Jim
AU - Radhakrishnan, Rajiv
AU - Pençe, Ayşegül Yay
AU - Erzin, Gamze
AU - Delespaul, Philippe
AU - Kenis, Gunter
AU - Luykx, Jurjen J
AU - Lin, Bochao D
AU - Akdede, Berna
AU - Binbay, Tolga
AU - Altınyazar, Vesile
AU - Yalınçetin, Berna
AU - Gümüş-Akay, Güvem
AU - Cihan, Burçin
AU - Soygür, Haldun
AU - Ulaş, Halis
AU - Cankurtaran, Eylem Şahin
AU - Kaymak, Semra Ulusoy
AU - Mihaljevic, Marina M
AU - Andric-Petrovic, Sanja
AU - Mirjanic, Tijana
AU - Bernardo, Miguel
AU - Mezquida, Gisela
AU - Amoretti, Silvia
AU - Bobes, Julio
AU - Saiz, Pilar A
AU - García-Portilla, Maria Paz
AU - Sanjuan, Julio
AU - Aguilar, Eduardo J
AU - Santos, José Luis
AU - Jiménez-López, Estela
AU - Arrojo, Manuel
AU - Carracedo, Angel
AU - López, Gonzalo
AU - González-Peñas, Javier
AU - Parellada, Mara
AU - Maric, Nadja P
AU - Atbaşoğlu, Cem
AU - Üçok, Alp
AU - Alptekin, Köksal
AU - Saka, Meram Can
AU - Aguglia, Eugenio
AU - Arango, Celso
AU - Rutten, Bart Pf
AU - Guloksuz, Sinan
AU - Genetic Risk and Outcome of Psychosis (GROUP) Investigators
N1 - Copyright © 2022. Published by Elsevier B.V.
PY - 2022/10
Y1 - 2022/10
N2 - Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples.
AB - Schizophrenia is frequently accompanied with social cognitive disturbances. Cannabis represents one established environmental factor associated with the onset and progression of schizophrenia. The present cross-sectional study aimed to investigate the association of facial emotion recognition (FER) performance with cannabis use in 2039 patients with schizophrenia, 2141 siblings, and 2049 healthy controls (HC). FER performance was measured using the Degraded Facial Affect Recognition Task (DFAR). Better FER performance as indicated by higher DFAR-total scores was associated with lifetime regular cannabis use in schizophrenia (B = 1.36, 95% CI 0.02 to 2.69), siblings (B = 2.17, 95% CI 0.79 to 3.56), and HC (B = 3.10, 95% CI 1.14 to 5.06). No associations were found between DFAR-total and current cannabis use. Patients with schizophrenia who started to use cannabis after the age of 16 showed better FER performance than patients who started earlier (B = 2.50, 95% CI 0.15 to 4.84) and non-users (B = 3.72, 95 CI 1.96 to 5.49). Better FER performance was found also in siblings who started to use cannabis after 16 compared to non-users (B = 2.37, 95% CI 0.58 to 4.16), while HC using cannabis performed better than non-users at DFAR-total regardless of the age at onset. Our findings suggest that lifetime regular cannabis use may be associated with better FER regardless of the psychosis risk, but that FER might be moderated by age at first use in people with higher genetic risk. Longitudinal studies may clarify whether there is a cause-and-effect relationship between cannabis use and FER performance in psychotic and non-psychotic samples.
U2 - 10.1016/j.euroneuro.2022.08.003
DO - 10.1016/j.euroneuro.2022.08.003
M3 - Article
C2 - 36055075
SN - 0924-977X
VL - 63
SP - 47
EP - 59
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
ER -